calen
defhl
2007-04-23T14:37:26Z
2007-03-05T09:31:39Z
2007-04-23T15:02:06Z
Imperial College
11.6568
10275
17160
0
255
5
1
False
False
| Deliverable number |
Deliverable title |
WP |
Lead |
Person-months |
Nature |
Dissemination level |
Delivery date |
| D1.5 |
Annual reports to EC |
1 |
Partner 1 |
12 |
R |
PU |
13, 25, 37 |
| D1.6 |
Annual audit of partner expenditure |
1 |
Partner 1 |
12 |
R |
PU |
13, 25, 37 |
| D1.7 |
Annual review of expenditure |
1 |
Partner 1 |
12 |
R |
PU |
13, 25, 37 |
| D2.1 |
Report of literature review |
2 |
Partner 14 |
6 |
R |
PU |
15 |
| D3.1 |
Phase II DNA samples at genotyping centres (CNG & GSF) |
3 |
Partner 3 |
6 |
O |
CO |
15 |
| D3.2 |
Phase II phenotypic and environmental data at data centre |
3 |
Partner 3 |
6 |
O |
CO |
18 |
| D3.3 |
Phase II genotypes to data centre |
3 |
Partner 3 |
2 |
O |
CO |
22 |
| D3.4 |
Phase II genotypes to local centres |
3 |
Partner 3 |
2 |
O |
CO |
22 |
| D3.5 |
Phase III DNA samples at CNG and GSF |
3 |
Partner 3 |
12 |
O |
CO |
21 |
| D3.6 |
Phase III Phenotypic and environmental data at data centre |
3 |
Partner 21 |
12 |
O |
CO |
21 |
| D3.10 |
Delivery of DNA from non-European Centres to genotyping centres |
3 |
Partner 1 |
24 |
O |
CO |
15 |
| D3.11 |
Completion of Phase I genotyping from GABRIEL WGA from non-European centres |
3 |
Partner 1 |
24 |
O |
CO |
24 |
| D3.12 |
Analysis of Phase I genotyping from non-European centres |
3 |
Partner 21 |
36 |
O |
CO |
27 |
| D4.3 |
Data entry mask for rural study questionnaires, serum IgE, bronchial challenge and throat swabs |
4 |
Partner 8 |
24 |
O |
CO |
24 |
| D4.5 |
Completed recruitment of all subjects in rural surveys |
4 |
Partner 8 |
256 |
O |
CO |
30 |
| D4.7 |
Archive of biological samples (DNA, RNA, cells and tissues) of patients with severe asthma |
4 |
Partner 1 |
18 |
O |
CO |
27 |
| D4.8 |
DNA samples from case-control clinic asthmatics |
4 |
Partner 2 |
48 |
O |
CO |
24 |
| D5.1 |
Acceptance and QC checking of all DNA samples at CNG & GSF |
5 |
Partner 3 |
12 |
O |
CO |
24 |
| D5.3 |
Phase II genotyping complete |
5 |
Partner 3 |
24 |
O |
CO |
20 |
|
| D5.4 |
Phase III genotyping complete |
5 |
Partner 3 |
24 |
O |
CO |
30 |
| D5.5 |
Proteomic examination of plasma asthmatics and controls |
5 |
Partner 2 |
4 |
O |
CO |
30 |
| D5.6 |
Proteomic examination of plasma farmers and controls |
5 |
Partner 2 |
4 |
O |
CO |
30 |
| D5.9 |
Database for phenotype and genotypes |
5 |
Partner 21 |
3 |
O |
CO |
13 |
| D5.11 |
Joint Phase II data analysed |
5 |
Partner 21 |
6 |
R |
PU |
22 |
| D6.2 |
Microbial components of dust samples from validation study |
6 |
Partner 8 |
6 |
O |
PU |
24 |
| D6.3 |
Components of milk samples from validation study |
6 |
Partner 8 |
6 |
O |
PU |
24 |
| D6.4 |
Revised protocols for full survey |
6 |
Partner 2 |
6 |
O |
PU |
30 |
| D6.9 |
Analyses of the effects of smoking, genes and environment in subjects from existing surveys |
6 |
Partner 20 |
18 |
R |
PU |
24 |
| D6.10 |
Analyses of the effects of genes and environment in industrial asthma |
6 |
Partner 11 |
12 |
R |
PU |
30 |
| D6.11 |
Extractions from pooled dust samples from rural areas in alpine regions and South-West Poland |
6 |
Partner 6 |
12 |
O |
CO |
30 |
| D7.1 |
Establishment of baseline genomic epithelial model |
7 |
Partner 1 |
12 |
O |
PU |
18 |
| D7.2 |
Knockdown of target genes by RNAi in epithelial model |
7 |
Partner 1 |
24 |
O |
CO |
30 |
|
| D7.3 |
Establishment of Dendritic Cell Th1 Th2 modulation model |
7 |
Partner 13 |
12 |
O |
CO |
15 |
| D7.5 |
Knockout of gene PCDH1 (protocadherin) in mouse |
7 |
Partner 20 |
12 |
O |
CO |
24 |
| D7.6 |
Test efects of PCDH1 knockout on cigarette smoke exposure |
7 |
Partner 20 |
24 |
O |
CO |
27 |
| D7.7 |
Test effects of environmental factors from WP6.4 on murine model of asthma |
7 |
Partner 16 |
36 |
O |
CO |
27 |
|
| D8.5 |
Selection of target from the results of WP3 and WP5 |
8 |
Partner 27 |
6 |
O |
CO |
18 |
| D8.6 |
Development of potential biotherapeutics against target |
8 |
Partner 27 |
36 |
O |
CO |
24 |
| D9.3 |
Call for 3-month visiting fellowships |
9 |
Partner 20 |
3 |
O |
PU |
15 |
| D9.4 |
Appointment of visting fellowships |
9 |
Partner 20 |
3 |
O |
PU |
18 |
9
1200
1200
15
3
28
8
False
False
| Deliverable number |
Deliverable title |
WP |
Lead |
Person-months |
Nature |
Dissemination level |
Delivery date |
New delivery date |
| D1.1 |
Signed Consortium Agreement |
1 |
Partner 1 |
3 |
O |
PP |
0 |
delivered |
| D1.2 |
Appointment of Project Management |
1 |
Partner 1 |
3 |
O |
PU |
1 |
delivered |
[1] Deliverable numbers in order of delivery dates: D1 – Dn |
| D1.3 |
Establishment of membership of all commitees |
1 |
Partner 1 |
1 |
O |
PU |
3 |
delivered |
[2] Please indicate the nature of the deliverable using one of the following codes: |
| D1.4 |
Establishment of meeting timetables and locations |
1 |
Partner 1 |
3 |
O |
PU |
3 |
delivered |
R = Report |
| D1.5 |
Annual reports to EC |
1 |
Partner 1 |
12 |
R |
PU |
13, 25, 37 |
13, 25, 37 |
P = Prototype |
| D1.6 |
Annual audit of partner expenditure |
1 |
Partner 1 |
12 |
R |
PU |
13, 25, 37 |
13, 25, 37 |
D = Demonstrator |
| D1.7 |
Annual review of expenditure |
1 |
Partner 1 |
12 |
R |
PU |
13, 25, 37 |
13, 25, 37 |
O = Other |
| M1.1 |
Signed Consortium Agreement |
1 |
Partner 1 |
|
O |
PU |
0 |
delivered |
[3] Please indicate the dissemination level using one of the following codes: |
| M1.2 |
Final Report to EC |
1 |
Partner 1 |
|
R |
PU |
48 |
48 |
PU = Public |
| D2.1 |
Report of literature review |
2 |
Partner 14 |
6 |
R |
PU |
12 |
15 |
PP = Restricted to other programme participants (including the Commission Services). |
| D2.2 |
Report on ethical practice in the consortium |
2 |
Partner 14 |
6 |
R |
PU |
12 |
delete |
RE = Restricted to a group specified by the consortium (including the Commission Services). |
| D2.3 |
Report of Focus Group Study |
2 |
Partner 14 |
6 |
R |
PU |
36 |
36 |
CO = Confidential, only for members of the consortium (including the Commission Services). |
| D2.4 |
Report on ethical practice in the EU |
2 |
Partner 14 |
6 |
R |
PU |
30 |
delete |
[4] Month in which the deliverables will be available. Month 1 marking the start of the project, and all delivery dates being relative to this start date. |
| M2.1 |
Formation of Ethics Board |
2 |
Partner 14 |
O |
PU |
3 |
delivered |
| M2.2 |
Review of partner policies for ethical conduct |
2 |
Partner 14 |
R |
PU |
9 |
delete |
| M2.3 |
Review of Legal and ethical literature |
2 |
Partner 14 |
R |
PU |
15 |
15 |
| M2.4 |
Review of differences in ethical practice within the EU |
2 |
Partner 14 |
R |
PU |
27 |
27 |
|
| M2.5 |
Report of Focus Group Study |
2 |
Partner 14 |
R |
PU |
36 |
36 |
| D3.1 |
Phase II DNA samples at genotyping centres (CNG & GSF) |
3 |
Partner 3 |
6 |
O |
CO |
3 |
15 |
| D3.2 |
Phase II phenotypic and environmental data at data centre |
3 |
Partner 3 |
6 |
O |
CO |
3 |
18 |
| D3.3 |
Phase II genotypes to data centre |
3 |
Partner 3 |
2 |
O |
CO |
12 |
22 |
| D3.4 |
Phase II genotypes to local centres |
3 |
Partner 3 |
2 |
O |
CO |
12 |
22 |
| D3.5 |
Phase III DNA samples at CNG and GSF |
3 |
Partner 3 |
12 |
O |
CO |
9 |
21 |
| D3.6 |
Phase III Phenotypic and environmental data at data centre |
3 |
Partner 21 |
12 |
O |
CO |
9 |
21 |
| D3.7 |
Phase III genotypes to data centre |
3 |
Partner 3 |
2 |
O |
CO |
21 |
33 |
| D3.8 |
Phase III genotypes to local centres |
3 |
Partner 3 |
2 |
O |
CO |
21 |
33 |
| D3.9 |
Detailed analyses of GG and GE interactions by partners |
3 |
Partner 21 |
116 |
R |
PU |
36 |
36 |
| M3.1 |
Acceptance and QC checking of all DNA samples at CNG & GSF |
3 |
Partner 3 |
O |
CO |
12 |
24 |
| M3.2 |
Transfer of Phase II genotypes to centres |
3 |
Partner 3 |
O |
CO |
12 |
21 |
| M3.3 |
Transfer of Phase III genotypes to centres |
3 |
Partner 3 |
O |
CO |
21 |
33 |
| M3.4 |
Completion of Phase III joint analysis |
3 |
Partner 21 |
R |
PU |
39 |
39 |
| D4.1 |
Development of common protocols for recruitment of rural and alpine study population |
4 |
Partner 8 |
6 |
O |
PU |
3 |
delivered |
| D4.2 |
Development of screening questionnaire for participation bias |
4 |
Partner 8 |
6 |
O |
PU |
6 |
delivered |
| D4.3 |
Data entry mask for rural study questionnaires, serum IgE, bronchial challenge and throat swabs |
4 |
Partner 8 |
6 |
O |
CO |
6 |
24 |
| D4.4 |
Establishment of quality control for rural study data handling |
4 |
Partner 8 |
6 |
O |
CO |
6 |
delivered |
| D4.5 |
Completed recruitment of all subjects in rural surveys |
4 |
Partner 8 |
256 |
O |
CO |
30 |
30 |
| D4.6 |
Establishment of protocols for characterisation of adults and children with severe asthma |
4 |
Partner 1 |
3 |
O |
PU |
3 |
delivered |
| D4.7 |
Archive of biological samples (DNA, RNA, cells and tissues) of patients with severe asthma |
4 |
Partner 1 |
18 |
O |
CO |
27 |
27 |
| D4.8 |
DNA samples from case-control clinic asthmatics |
4 |
Partner 2 |
48 |
O |
CO |
12 |
24 |
| M4.1 |
Completed survey of rural and alpine case and controls with subject and environmental samples for laboratory testing |
4 |
Partner 8 |
O |
CO |
30 |
30 |
| M4.2 |
Established cell, tissue and fluid biobank from severe asthmatics |
4 |
Partner 1 |
O |
CO |
27 |
27 |
| M4.3 |
Completion of MAGICS clinic case-control collections |
4 |
Partner 2 |
O |
CO |
12 |
21 |
| D5.1 |
Acceptance and QC checking of all DNA samples at CNG & GSF |
5 |
Partner 3 |
12 |
O |
CO |
9 |
24 |
| D5.2 |
Whole genome association genotyping (Phase I) complete |
5 |
Partner 3 |
24 |
O |
CO |
6 |
delivered |
| D5.3 |
Phase II genotyping complete |
5 |
Partner 3 |
24 |
O |
CO |
9 |
20 |
| D5.4 |
Phase III genotyping complete |
5 |
Partner 3 |
24 |
O |
CO |
18 |
30 |
| D5.5 |
Proteomic examination of plasma asthmatics and controls |
5 |
Partner 2 |
4 |
O |
CO |
18 |
30 |
| D5.6 |
Proteomic examination of plasma farmers and controls |
5 |
Partner 2 |
4 |
O |
CO |
18 |
30 |
| D5.7 |
Proteomic examination of severe asthma samples |
5 |
Partner 1 |
4 |
O |
CO |
33 |
33 |
| D5.8 |
Population screening of novel proteins of interest |
5 |
Partner 4 |
24 |
O |
CO |
45 |
45 |
| D5.9 |
Database for phenotype and genotypes |
5 |
Partner 21 |
3 |
O |
CO |
6 |
13 |
| D5.10 |
Whole genome data analysed |
5 |
Partner 1 |
6 |
R |
PU |
9 |
11 |
| D5.11 |
Joint Phase II data analysed |
5 |
Partner 21 |
6 |
R |
PU |
15 |
22 |
| D5.12 |
Joint Phase III data analysed |
5 |
Partner 21 |
6 |
R |
PU |
36 |
36 |
| D5.13 |
Genomic data integrated and analysed |
5 |
Partner 21 |
6 |
R |
PU |
39 |
39 |
| D5.14 |
Microarry analyses of normal and diseased cells |
5 |
Partner 1 |
36 |
O |
PU |
39 |
39 |
| D5.15 |
16S RNA sequencing of dust and milk samples |
5 |
Partner 1 |
36 |
O |
PU |
36 |
36 |
| M5.1 |
Completion of Phase I (whole genome) genotyping |
5 |
Partner 3 |
O |
CO |
6 |
11 |
| M5.2 |
Completion of Phase II genotyping |
5 |
Partner 3 |
O |
CO |
9 |
30 |
| M5.3 |
Completion of Phase III genotyping |
5 |
Partner 3 |
O |
CO |
21 |
36 |
| M5.4 |
Identification of novel serum proteins from asthmatics |
5 |
Partner 2 |
O |
CO |
15 |
27 |
| M5.5 |
Identification of novel serum proteins from farmers |
5 |
Partner 2 |
O |
CO |
15 |
27 |
| M5.6 |
Identification of novel proteins from severe asthmatics |
5 |
Partner 1 |
O |
CO |
33 |
33 |
| M5.7 |
Validation of proteomic studies in representative populations |
5 |
Partner 4 |
O |
CO |
45 |
45 |
| M5.8 |
Joint Phase II data analysed |
5 |
Partner 21 |
R |
PU |
18 |
22 |
| M5.9 |
Joint Phase III data analysed |
5 |
Partner 21 |
R |
PU |
42 |
42 |
| M5.11 |
Genomic analysis of common microbial components of milk and dust |
5 |
Partner 1 |
O |
PU |
42 |
42 |
| D6.1 |
Detailed protocols for initial field study |
6 |
Partner 2 |
6 |
O |
PU |
6 |
delivered |
| D6.2 |
Microbial components of dust samples from validation study |
6 |
Partner 8 |
6 |
O |
PU |
12 |
24 |
| D6.3 |
Components of milk samples from validation study |
6 |
Partner 8 |
6 |
O |
PU |
12 |
24 |
| D6.4 |
Revised protocols for full survey |
6 |
Partner 2 |
6 |
O |
PU |
15 |
24 |
| D6.5 |
Results of field testing of rural subjects |
6 |
Partner 8 |
12 |
R |
CO |
36 |
36 |
| D6.6 |
Archive of dust samples from full rural survey |
6 |
Partner 8 |
3 |
O |
CO |
36 |
36 |
| D6.7 |
Archive of milk samples from full rural survey |
6 |
Partner 8 |
3 |
O |
CO |
36 |
36 |
| D6.8 |
Analyses of the results of advanced surveys |
6 |
Partner 8 |
12 |
R |
PU |
45 |
45 |
| D6.9 |
Analyses of the effects of smoking, genes and environment in subjects from existing surveys |
6 |
Partner 20 |
18 |
R |
PU |
24 |
24 |
| D6.10 |
Analyses of the effects of genes and environment in industrial asthma |
6 |
Partner 11 |
12 |
R |
PU |
30 |
30 |
| D6.11 |
Extractions from pooled dust samples from rural areas in alpine regions and South-West Poland |
6 |
Partner 6 |
12 |
O |
CO |
30 |
30 |
| D6.12 |
Fractionation and purification of dust samples |
6 |
Partner 6 |
18 |
O |
CO |
42 |
42 |
| M6.1 |
Completion of field work for dust and milk validation study |
6 |
Partner 8 |
O |
CO |
15 |
24 |
| M6.2 |
Completion of analyses of milk and dust from validation study |
6 |
Partner 8 |
R |
PU |
15 |
24 |
| M6.3 |
Completion of field testing of full survey |
6 |
Partner 8 |
O |
CO |
36 |
36 |
| M6.4 |
Completion of analyses of results of advanced survey |
6 |
Partner 8 |
R |
PU |
45 |
45 |
| M6.5 |
Fractionation and purification of dust samples |
6 |
Partner 6 |
O |
CO |
42 |
42 |
| D7.1 |
Establishment of baseline genomic epithelial model |
7 |
Partner 1 |
12 |
O |
PU |
18 |
18 |
| D7.2 |
Knockdown of target genes by RNAi in epithelial model |
7 |
Partner 1 |
24 |
O |
CO |
30 |
30 |
| D7.3 |
Establishment of Dendritic Cell Th1 Th2 modulation model |
7 |
Partner 13 |
12 |
O |
CO |
15 |
15 |
| D7.4 |
Identification of candidate compounds/ structures able to modulate the immune system away from Th2 |
7 |
Partner 6 |
24 |
O |
PU |
42 |
42 |
| D7.5 |
Knockout of gene PCDH1 (protocadherin) in mouse |
7 |
Partner 20 |
12 |
O |
CO |
24 |
24 |
| D7.6 |
Test efects of PCDH1 knockout on cigarette smoke exposure |
7 |
Partner 20 |
24 |
O |
CO |
27 |
24 |
| D7.7 |
Test effects of environmental factors from WP6.4 on murine model of asthma |
7 |
Partner 16 |
36 |
O |
CO |
27 |
27 |
| M7.1 |
Measurement of the effects of IL-1and LPS stimulation in the presence and absence of cigarette smoke in epithelial cell model |
7 |
Partner 1 |
O |
PU |
24 |
24 |
| M7.2 |
Measurement of effects of gene knockdown in epithelial cell model |
7 |
Partner 1 |
O |
CO |
30 |
30 |
| M7.3 |
Identification of candidate compounds/ structures able to modulate the immune system away from Th2 |
7 |
Partner 13 |
O |
CO |
30 |
| M7.4 |
Priority list of compounds that are to be tested further structurally |
7 |
Partner 6 |
O |
PU |
24 |
24 |
| M7.5 |
Measurement of effects of PCDH1 (protocadherin) knockout in mouse model of asthma |
7 |
Partner 20 |
O |
CO |
24 |
24 |
| D8.1 |
Development of agonists and antagonists for Toll-like receptors |
8 |
Partner 24 |
24 |
O |
CO |
18 |
delivered |
| D8.2 |
Development of agonists and antagonists for targets identified in WP5 |
8 |
Partner 24 |
24 |
O |
CO |
42 |
42 |
| D8.3 |
Completed recruitment of pharmacogenetic study population |
8 |
Partner 23 |
36 |
O |
CO |
18 |
36 |
| D8.4 |
Validation and commercialization of biomarkers for use in drug development, molecular diagnostics and improved patient care |
8 |
Partner 23 |
36 |
O |
CO |
36 |
36 |
| D8.5 |
Selection of target from the results of WP3 and WP5 |
8 |
Partner 27 |
6 |
O |
CO |
12 |
18 |
| D8.6 |
Development of potential biotherapeutics against target |
8 |
Partner 27 |
36 |
O |
CO |
18 |
24 |
| M8.1 |
Development of agonists and antagonists for Toll-like receptors |
8 |
Partner 24 |
O |
CO |
18 |
delivered |
| M8.2 |
Completed recruitment of pharmacogenetic study population |
8 |
Partner 23 |
O |
CO |
18 |
36 |
| M8.3 |
Development of effective biomarkers for asthma therapeutics |
8 |
Partner 27 |
O |
CO |
42 |
42 |
| M8.4 |
Development of potential biotherapeutic for asthma |
8 |
Partner 27 |
O |
CO |
45 |
45 |
| D9.1 |
Call for three 3-year PhD studentships |
9 |
Partner 20 |
3 |
O |
PU |
3 |
delivered |
| D9.2 |
Appointment of PhD studentships |
9 |
Partner 20 |
3 |
O |
PU |
6 |
delivered |
| D9.3 |
Call for 3-month visiting fellowships |
9 |
Partner 20 |
3 |
O |
PU |
3 |
delivered |
| D9.4 |
Appointment of visting fellowships |
9 |
Partner 20 |
3 |
O |
PU |
6 |
delivered |
| D9.5 |
Organisation of workshops |
9 |
Partner 2 |
12 |
O |
PU |
6 |
delivered |
| M9.1 |
Appointment of PhD studentships |
9 |
Partner 20 |
R |
PU |
6 |
delivered |
| M9.2 |
Appointment of visiting fellowships |
9 |
Partner 20 |
R |
PU |
6 |
delivered |
| M9.3 |
Organisation of workshops |
9 |
Partner 2 |
R |
PU |
6 |
delivered |
9
75
300
300
8
3
2
9
R3C10:R14C22
False
False
| Deliverable number |
Deliverable title |
WP |
date due |
Actual/Forecast deliverable date |
Estimated indicative Person-months |
Used indicative person-months |
Lead |
| D1.1 |
Signed Consortium Agreement |
1 |
0 |
0 |
3 |
3 |
Partner 1 |
| D1.2 |
Appointment of Project Management |
1 |
1 |
1 |
3 |
3 |
Partner 1 |
| D1.3 |
Establishment of membership of all commitees |
1 |
3 |
3 |
1 |
2 |
Partner 1 |
| D1.4 |
Establishment of meeting timetables and locations |
1 |
3 |
3 |
3 |
3 |
Partner 1 |
| D1.5 |
Annual reports to EC |
1 |
13, 25, 37 |
13, 25, 37 |
12 |
12 |
Partner 1 |
| D1.6 |
Annual audit of partner expenditure |
1 |
13, 25, 37 |
13, 25, 37 |
12 |
12 |
Partner 1 |
| D1.7 |
Annual review of expenditure |
1 |
13, 25, 37 |
13, 25, 37 |
12 |
12 |
Partner 1 |
| D2.1 |
Report of literature review |
2 |
12 |
15 |
6 |
6 |
Partner 14 |
| D2.2 |
Report of Focus Group Study |
2 |
36 |
36 |
6 |
6 |
Partner 14 |
| D3.1 |
Phase II DNA samples at genotyping centres (CNG & GSF) |
3 |
3 |
15 |
6 |
6 |
Partner 3 |
| D3.2 |
Phase II phenotypic and environmental data at data centre |
3 |
3 |
18 |
6 |
6 |
Partner 3 |
| D3.3 |
Phase II genotypes to data centre |
3 |
12 |
22 |
2 |
2 |
Partner 3 |
| D3.4 |
Phase II genotypes to local centres |
3 |
12 |
22 |
2 |
2 |
Partner 3 |
| D3.5 |
Phase III DNA samples at CNG and GSF |
3 |
9 |
21 |
12 |
12 |
Partner 3 |
| D3.6 |
Phase III Phenotypic and environmental data at data centre |
3 |
9 |
21 |
12 |
12 |
Partner 21 |
| D3.7 |
Phase III genotypes to data centre |
3 |
21 |
33 |
2 |
2 |
Partner 3 |
| D3.8 |
Phase III genotypes to local centres |
3 |
21 |
33 |
2 |
2 |
Partner 3 |
| D3.9 |
Detailed analyses of GG and GE interactions by partners |
3 |
36 |
36 |
116 |
116 |
Partner 21 |
| D4.1 |
Development of common protocols for recruitment of rural and alpine study population |
4 |
3 |
delivered |
6 |
6 |
Partner 8 |
| D4.2 |
Development of screening questionnaire for participation bias |
4 |
6 |
delivered |
6 |
6 |
Partner 8 |
| D4.3 |
Data entry mask for rural study questionnaires, serum IgE, bronchial challenge and throat swabs |
4 |
6 |
24 |
6 |
6 |
Partner 8 |
| D4.4 |
Establishment of quality control for rural study data handling |
4 |
6 |
delivered |
6 |
6 |
Partner 8 |
| D4.5 |
Completed recruitment of all subjects in rural surveys |
4 |
30 |
30 |
256 |
256 |
Partner 8 |
| D4.6 |
Establishment of protocols for characterisation of adults and children with severe asthma |
4 |
3 |
delivered |
3 |
3 |
Partner 1 |
| D4.7 |
Archive of biological samples (DNA, RNA, cells and tissues) of patients with severe asthma |
4 |
27 |
27 |
18 |
18 |
Partner 1 |
| D4.8 |
DNA samples from case-control clinic asthmatics |
4 |
12 |
24 |
48 |
48 |
Partner 2 |
| D5.1 |
Acceptance and QT checking of all DNA samples at CNG & GSF |
5 |
9 |
24 |
12 |
12 |
Partner 3 |
| D5.2 |
Whole genome association genotyping (Phase I) complete |
5 |
6 |
delivered |
24 |
24 |
Partner 3 |
| D5.3 |
Phase II genotyping complete |
5 |
9 |
20 |
24 |
24 |
Partner 3 |
| D5.4 |
Phase III genotyping complete |
5 |
18 |
30 |
24 |
24 |
Partner 3 |
| D5.5 |
Proteomic examination of plasma asthmatics and controls |
5 |
18 |
30 |
4 |
4 |
Partner 2 |
| D5.6 |
Proteomic examination of plasma farmers and controls |
5 |
18 |
30 |
4 |
4 |
Partner 2 |
| D5.7 |
Proteomic examination of severe asthma samples |
5 |
33 |
33 |
4 |
4 |
Partner 1 |
| D5.8 |
Population screening of novel proteins of interest |
5 |
45 |
45 |
24 |
24 |
Partner 4 |
| D5.9 |
Database for phenotype and genotypes |
5 |
6 |
13 |
3 |
3 |
Partner 21 |
| D5.10 |
Whole genome data analysed |
5 |
9 |
11 |
6 |
6 |
Partner 1 |
| D5.11 |
Joint Phase II data analysed |
5 |
15 |
22 |
6 |
6 |
Partner 21 |
| D5.12 |
Joint Phase III data analysed |
5 |
36 |
36 |
6 |
6 |
Partner 21 |
| D5.13 |
Genomic data integrated and analysed |
5 |
39 |
39 |
6 |
6 |
Partner 21 |
| D5.14 |
Microarry analyses of normal and diseased cells |
5 |
39 |
39 |
36 |
36 |
Partner 1 |
| D5.15 |
16S RNA sequencing of dust and milk samples |
5 |
36 |
36 |
36 |
36 |
Partner 1 |
| D6.1 |
Detailed protocols for initial field study |
6 |
6 |
delivered |
6 |
6 |
Partner 2 |
| D6.2 |
Microbial components of dust samples from validation study |
6 |
12 |
24 |
6 |
6 |
Partner 8 |
| D6.3 |
Components of milk samples from validation study |
6 |
12 |
24 |
6 |
6 |
Partner 8 |
| D6.4 |
Revised protocols for full survey |
6 |
15 |
24 |
6 |
6 |
Partner 2 |
| D6.5 |
Results of field testing of rural subjects |
6 |
36 |
36 |
12 |
12 |
Partner 8 |
| D6.6 |
Archive of dust samples from full rural survey |
6 |
36 |
36 |
3 |
3 |
Partner 8 |
| D6.7 |
Archive of milk samples from full rural survey |
6 |
36 |
36 |
3 |
3 |
Partner 8 |
| D6.8 |
Analyses of the results of advanced surveys |
6 |
45 |
45 |
12 |
12 |
Partner 8 |
| D6.9 |
Analyses of the effects of smoking, genes and environment in subjects from existing surveys |
6 |
24 |
24 |
18 |
18 |
Partner 20 |
| D6.10 |
Analyses of the effects of genes and environment in industrial asthma |
6 |
30 |
30 |
12 |
12 |
Partner 11 |
| D6.11 |
Extractions from pooled dust samples from rural areas in alpine regions and South-West Poland |
6 |
30 |
30 |
12 |
12 |
Partner 6 |
| D6.12 |
Fractionation and purification of dust samples |
6 |
42 |
42 |
18 |
18 |
Partner 6 |
| D7.1 |
Establishment of baseline genomic epithelial model |
7 |
18 |
18 |
12 |
12 |
Partner 1 |
| D7.2 |
Knockdown of target genes by RNAi in epithelial model |
7 |
30 |
30 |
24 |
24 |
Partner 1 |
| D7.3 |
Establishment of Dendritic Cell Th1 Th2 modulation model |
7 |
15 |
15 |
12 |
12 |
Partner 13 |
| D7.4 |
Identification of candidate compounds/ structures able to modulate the immune system away from Th2 |
7 |
42 |
42 |
24 |
24 |
Partner 6 |
| D7.5 |
Knockout of gene PCDH1 (protocadherin) in mouse |
7 |
24 |
24 |
12 |
12 |
Partner 20 |
| D7.6 |
Test efects of PCDH1 knockout on cigarette smoke exposure |
7 |
27 |
24 |
24 |
24 |
Partner 20 |
| D7.7 |
Test effects of environmental factors from WP6.4 on murine model of asthma |
7 |
27 |
27 |
36 |
36 |
Partner 16 |
| D8.1 |
Development of agonists and antagonists for Toll-like receptors |
8 |
18 |
delivered |
24 |
24 |
Partner 24 |
| D8.2 |
Development of agonists and antagonists for targets identified in WP5 |
8 |
42 |
42 |
24 |
24 |
Partner 24 |
| D8.3 |
Completed recruitment of pharmacogenetic study population |
8 |
18 |
36 |
36 |
36 |
Partner 23 |
| D8.4 |
Validation and commercialization of biomarkers for use in drug development, molecular diagnostics and improved patient care |
8 |
36 |
36 |
36 |
36 |
Partner 23 |
| D8.5 |
Selection of target from the results of WP3 and WP5 |
8 |
12 |
18 |
6 |
6 |
Partner 27 |
| D8.6 |
Development of potential biotherapeutics against target |
8 |
18 |
24 |
36 |
36 |
Partner 27 |
| D9.1 |
Call for three 3-year PhD studentships |
9 |
3 |
delivered |
3 |
3 |
Partner 20 |
| D9.2 |
Appointment of PhD studentships |
9 |
6 |
delivered |
3 |
3 |
Partner 20 |
| D9.3 |
Call for 3-month visiting fellowships |
9 |
3 |
delivered |
3 |
3 |
Partner 20 |
| D9.4 |
Appointment of visting fellowships |
9 |
6 |
delivered |
3 |
3 |
Partner 20 |
| D9.5 |
Organisation of workshops |
9 |
6 |
delivered |
12 |
12 |
Partner 2 |
| Deliverable number |
Deliverable title |
WP |
date due |
Actual/Forecast deliverable date |
Estimated indicative Person-months |
Used indicative person-months |
Lead |
| D5.1 |
Acceptance and QT checking of all DNA samples at CNG & GSF |
5 |
9 |
24 |
12 |
12 |
Partner 3 |
| D5.2 |
Whole genome association genotyping (Phase I) complete |
5 |
6 |
delivered |
24 |
24 |
Partner 3 |
| D5.3 |
Phase II genotyping complete |
5 |
9 |
20 |
24 |
24 |
Partner 3 |
| D5.4 |
Phase III genotyping complete |
5 |
18 |
30 |
24 |
24 |
Partner 3 |
| D5.5 |
Proteomic examination of plasma asthmatics and controls |
5 |
18 |
30 |
4 |
4 |
Partner 2 |
| D5.6 |
Proteomic examination of plasma farmers and controls |
5 |
18 |
30 |
4 |
4 |
Partner 2 |
| D5.7 |
Proteomic examination of severe asthma samples |
5 |
33 |
33 |
4 |
4 |
Partner 1 |
| D5.8 |
Population screening of novel proteins of interest |
5 |
45 |
45 |
24 |
24 |
Partner 4 |
| D5.9 |
Database for phenotype and genotypes |
5 |
6 |
15 |
3 |
3 |
Partner 21 |
| D5.10 |
Whole genome data analysed |
5 |
9 |
delivered |
6 |
6 |
Partner 1 |
| D5.11 |
Joint Phase II data analysed |
5 |
15 |
22 |
6 |
6 |
Partner 21 |
| D5.12 |
Joint Phase III data analysed |
5 |
36 |
36 |
6 |
6 |
Partner 21 |
| D5.13 |
Genomic data integrated and analysed |
5 |
39 |
39 |
6 |
6 |
Partner 21 |
| D5.14 |
Microarry analyses of normal and diseased cells |
5 |
39 |
39 |
36 |
36 |
Partner 1 |
| D5.15 |
16S RNA sequencing of dust and milk samples |
5 |
36 |
36 |
36 |
36 |
Partner 1 |
| D6.1 |
Detailed protocols for initial field study |
6 |
6 |
delivered |
6 |
6 |
Partner 2 |
| D6.2 |
Microbial components of dust samples from validation study |
6 |
12 |
24 |
6 |
6 |
Partner 8 |
| D6.3 |
Components of milk samples from validation study |
6 |
12 |
24 |
6 |
6 |
Partner 8 |
| D6.4 |
Revised protocols for full survey |
6 |
15 |
24 |
6 |
6 |
Partner 2 |
| D6.5 |
Results of field testing of rural subjects |
6 |
36 |
36 |
12 |
12 |
Partner 8 |
| D6.6 |
Archive of dust samples from full rural survey |
6 |
36 |
36 |
3 |
3 |
Partner 8 |
| D6.7 |
Archive of milk samples from full rural survey |
6 |
36 |
36 |
3 |
3 |
Partner 8 |
| D6.8 |
Analyses of the results of advanced surveys |
6 |
45 |
45 |
12 |
12 |
Partner 8 |
| D6.9 |
Analyses of the effects of smoking, genes and environment in subjects from existing surveys |
6 |
24 |
24 |
18 |
18 |
Partner 20 |
| D6.10 |
Analyses of the effects of genes and environment in industrial asthma |
6 |
30 |
12 |
12 |
Partner 11 |
| D6.11 |
Extractions from pooled dust samples from rural areas in alpine regions and South-West Poland |
6 |
30 |
30 |
12 |
12 |
Partner 6 |
| D6.12 |
Fractionation and purification of dust samples |
6 |
42 |
42 |
18 |
18 |
Partner 6 |
| D7.1 |
Establishment of baseline genomic epithelial model |
7 |
18 |
18 |
12 |
12 |
Partner 1 |
| D7.2 |
Knockdown of target genes by RNAi in epithelial model |
7 |
30 |
30 |
24 |
24 |
Partner 1 |
| D7.3 |
Establishment of Dendritic Cell Th1 Th2 modulation model |
7 |
15 |
12 |
12 |
Partner 13 |
| D7.4 |
Identification of candidate compounds/ structures able to modulate the immune system away from Th2 |
7 |
42 |
42 |
24 |
24 |
Partner 6 |
| D7.5 |
Knockout of gene PCDH1 (protocadherin) in mouse |
7 |
24 |
24 |
12 |
12 |
Partner 20 |
| D7.6 |
Test efects of PCDH1 knockout on cigarette smoke exposure |
7 |
27 |
24 |
24 |
24 |
Partner 20 |
| D7.7 |
Test effects of environmental factors from WP6.4 on murine model of asthma |
7 |
27 |
27 |
36 |
36 |
Partner 16 |
| D8.1 |
Development of agonists and antagonists for Toll-like receptors |
8 |
18 |
delivered |
24 |
24 |
Partner 24 |
| D8.2 |
Development of agonists and antagonists for targets identified in WP5 |
8 |
42 |
42 |
24 |
24 |
Partner 24 |
| D8.3 |
Completed recruitment of pharmacogenetic study population |
8 |
18 |
36 |
36 |
36 |
Partner 23 |
| D8.4 |
Validation and commercialization of biomarkers for use in drug development, molecular diagnostics and improved patient care |
8 |
36 |
36 |
36 |
36 |
Partner 23 |
| D8.5 |
Selection of target from the results of WP3 and WP5 |
8 |
3 |
18 |
6 |
6 |
Partner 27 |
| D8.6 |
Development of potential biotherapeutics against target |
8 |
15 |
15 |
36 |
36 |
Partner 27 |
| D9.1 |
Call for three 3-year PhD studentships |
9 |
3 |
delivered |
3 |
3 |
Partner 20 |
| D9.2 |
Appointment of PhD studentships |
9 |
6 |
delivered |
3 |
3 |
Partner 20 |
| D9.3 |
Call for 3-month visiting fellowships |
9 |
3 |
delivered |
3 |
3 |
Partner 20 |
| D9.4 |
Appointment of visting fellowships |
9 |
6 |
delivered |
3 |
3 |
Partner 20 |
| D9.5 |
Organisation of workshops |
9 |
6 |
delivered |
12 |
12 |
Partner 2 |
9
300
300
102
3
21
1
False
False
| Milestone number |
Deliverable title |
WP |
Lead |
Date due |
Actual/Forecast deliverable date |
| M1.1 |
Signed Consortium Agreement |
1 |
Partner 1 |
0 |
0 |
| M1.2 |
Final Report to EC |
1 |
Partner 1 |
48 |
48 |
| M2.1 |
Formation of Ethics Board |
2 |
Partner 14 |
3 |
6 |
| M2.2 |
Review of Legal and ethical literature |
2 |
Partner 14 |
15 |
15 |
| M2.3 |
Review of differences in ethical practice within the EU |
2 |
Partner 14 |
27 |
27 |
| M2.4 |
Report of Focus Group Study |
2 |
Partner 14 |
36 |
36 |
| M3.1 |
Acceptance and QC checking of all DNA samples at CNG & GSF |
3 |
Partner 3 |
12 |
24 |
| M3.2 |
Transfer of Phase II genotypes to centres |
3 |
Partner 3 |
12 |
21 |
| M3.3 |
Transfer of Phase III genotypes to centres |
3 |
Partner 3 |
21 |
33 |
| M3.4 |
Completion of Phase III joint analysis |
3 |
Partner 21 |
39 |
39 |
| M4.1 |
Completed survey of rural and alpine case and controls with subject and environmental samples for laboratory testing |
4 |
Partner 8 |
30 |
30 |
| M4.2 |
Established cell, tissue and fluid biobank from severe asthmatics |
4 |
Partner 1 |
27 |
27 |
| M4.3 |
Completion of MAGICS clinic case-control collections |
4 |
Partner 2 |
12 |
12 |
| M5.1 |
Completion of Phase I (whole genome) genotyping |
5 |
Partner 3 |
6 |
11 |
| M5.2 |
Completion of Phase II genotyping |
5 |
Partner 3 |
9 |
30 |
| M5.3 |
Completion of Phase III genotyping |
5 |
Partner 3 |
21 |
36 |
| M5.4 |
Identification of novel serum proteins from asthmatics |
5 |
Partner 2 |
15 |
27 |
| M5.5 |
Identification of novel serum proteins from farmers |
5 |
Partner 2 |
15 |
27 |
| M5.6 |
Identification of novel proteins from severe asthmatics |
5 |
Partner 1 |
33 |
33 |
| M5.7 |
Validation of proteomic studies in representative populations |
5 |
Partner 4 |
45 |
45 |
| M5.8 |
Joint Phase II data analysed |
5 |
Partner 21 |
18 |
22 |
| M5.9 |
Joint Phase III data analysed |
5 |
Partner 21 |
42 |
42 |
| M5.11 |
Genomic analysis of common microbial components of milk and dust |
5 |
Partner 1 |
42 |
42 |
| M6.1 |
Completion of field work for dust and milk validation study |
6 |
Partner 8 |
15 |
24 |
| M6.2 |
Completion of analyses of milk and dust from validation study |
6 |
Partner 8 |
15 |
24 |
| M6.3 |
Completion of field testing of full survey |
6 |
Partner 8 |
36 |
36 |
| M6.4 |
Completion of analyses of results of advanced survey |
6 |
Partner 8 |
45 |
45 |
| M6.5 |
Fractionation and purification of dust samples |
6 |
Partner 6 |
42 |
42 |
| M7.1 |
Measurement of the effects of IL-1and LPS stimulation in the presence and absence of cigarette smoke in epithelial cell model |
7 |
Partner 1 |
24 |
24 |
| M7.2 |
Measurement of effects of gene knockdown in epithelial cell model |
7 |
Partner 1 |
30 |
30 |
| M7.3 |
Identification of candidate compounds/ structures able to modulate the immune system away from Th2 |
7 |
Partner 13 |
30 |
30 |
| M7.4 |
Priority list of compounds that are to be tested further structurally |
7 |
Partner 6 |
24 |
24 |
| M7.5 |
Measurement of effects of PCDH1 (protocadherin) knockout in mouse model of asthma |
7 |
Partner 20 |
24 |
24 |
| M8.1 |
Development of agonists and antagonists for Toll-like receptors |
8 |
Partner 24 |
18 |
9 |
| M8.2 |
Completed recruitment of pharmacogenetic study population |
8 |
Partner 23 |
18 |
36 |
| M8.3 |
Development of effective biomarkers for asthma therapeutics |
8 |
Partner 27 |
42 |
42 |
| M8.4 |
Development of potential biotherapeutic for asthma |
8 |
Partner 27 |
45 |
45 |
| M9.1 |
Appointment of PhD studentships |
9 |
Partner 20 |
6 |
6 |
| M9.2 |
Appointment of visiting fellowships |
9 |
Partner 20 |
6 |
6 |
| M9.3 |
Organisation of workshops |
9 |
Partner 2 |
6 |
6 |
9
300
300
3
C1:C6
False
False
| Milestone number |
Deliverable title |
WP |
Nature |
Delivery Date |
|
|
|
|
|
| M2.2 |
Review of Legal and ethical literature |
2 |
RTD/Innovation |
15 |
| M2.3 |
Review of differences in ethical practice within the EU |
2 |
RTD/Innovation |
27 |
| M3.1 |
Acceptance and QC checking of all DNA samples at CNG & GSF |
3 |
RTD/Innovation |
24 |
| M3.2 |
Transfer of Phase II genotypes to centres |
3 |
RTD/Innovation |
21 |
| M3.5 |
Analysis of Phase I genotyping of non-european samples |
3 |
RTD/Innovation |
27 |
| M4.1 |
Completed survey of rural and alpine case and controls with subject and environmental samples for laboratory testing |
4 |
RTD/Innovation |
30 |
| M4.2 |
Established cell, tissue and fluid biobank from severe asthmatics |
4 |
RTD/Innovation |
27 |
| M4.3 |
Completion of MAGICS clinic case-control collections |
4 |
RTD/Innovation |
21 |
| M5.2 |
Completion of Phase II genotyping |
5 |
RTD/Innovation |
20 |
| M5.4 |
Identification of novel serum proteins from asthmatics |
5 |
RTD/Innovation |
27 |
| M5.5 |
Identification of novel serum proteins from farmers |
5 |
RTD/Innovation |
27 |
| M5.8 |
Joint Phase II data analysed |
5 |
RTD/Innovation |
22 |
| M6.1 |
Completion of field work for dust and milk validation study |
6 |
RTD/Innovation |
24 |
| M6.2 |
Completion of analyses of milk and dust from validation study |
6 |
RTD/Innovation |
30 |
| M7.1 |
Measurement of the effects of IL-1and LPS stimulation in the presence and absence of cigarette smoke in epithelial cell model |
7 |
RTD/Innovation |
24 |
| M7.2 |
Measurement of effects of gene knockdown in epithelial cell model |
7 |
RTD/Innovation |
30 |
| M7.3 |
Identification of candidate compounds/ structures able to modulate the immune system away from Th2 |
7 |
RTD/Innovation |
30 |
| M7.4 |
Priority list of compounds that are to be tested further structurally |
7 |
RTD/Innovation |
24 |
| M7.5 |
Measurement of effects of PCDH1 (protocadherin) knockout in mouse model of asthma |
7 |
RTD/Innovation |
30 |
| M9.2 |
Appointment of visiting fellowships |
9 |
Training |
18 |
9
1200
1200
5
3
R1C1:R22C5
False
False
| Deliverable number |
Deliverable title |
WP |
Lead |
Person-months |
Nature |
Dissemination level |
Delivery date |
| D1.5 |
Annual reports to EC |
1 |
Partner 1 |
12 |
R |
PU |
13, 25, 37 |
| D1.6 |
Annual audit of partner expenditure |
1 |
Partner 1 |
12 |
R |
PU |
13, 25, 37 |
| D1.7 |
Annual review of expenditure |
1 |
Partner 1 |
12 |
R |
PU |
13, 25, 37 |
| D2.1 |
Report of literature review |
2 |
Partner 14 |
6 |
R |
PU |
15 |
| D3.1 |
Phase II DNA samples at genotyping centres (CNG & GSF) |
3 |
Partner 3 |
6 |
O |
CO |
15 |
| D3.2 |
Phase II phenotypic and environmental data at data centre |
3 |
Partner 3 |
6 |
O |
CO |
18 |
| D3.3 |
Phase II genotypes to data centre |
3 |
Partner 3 |
2 |
O |
CO |
22 |
| D3.4 |
Phase II genotypes to local centres |
3 |
Partner 3 |
2 |
O |
CO |
22 |
| D3.5 |
Phase III DNA samples at CNG and GSF |
3 |
Partner 3 |
12 |
O |
CO |
21 |
| D3.6 |
Phase III Phenotypic and environmental data at data centre |
3 |
Partner 21 |
12 |
O |
CO |
21 |
| D3.10 |
Delivery of DNA from non-European Centres to genotyping centres |
3 |
Partner 1 |
24 |
O |
CO |
15 |
| D3.11 |
Completion of Phase I genotyping from GABRIEL WGA from non-European centres |
3 |
Partner 1 |
24 |
O |
CO |
24 |
| D3.12 |
Analysis of Phase I genotyping from non-European centres |
3 |
Partner 21 |
36 |
O |
CO |
27 |
| D4.3 |
Data entry mask for rural study questionnaires, serum IgE, bronchial challenge and throat swabs |
4 |
Partner 8 |
24 |
O |
CO |
24 |
| D4.5 |
Completed recruitment of all subjects in rural surveys |
4 |
Partner 8 |
256 |
O |
CO |
30 |
| D4.7 |
Archive of biological samples (DNA, RNA, cells and tissues) of patients with severe asthma |
4 |
Partner 1 |
18 |
O |
CO |
27 |
| D4.8 |
DNA samples from case-control clinic asthmatics |
4 |
Partner 2 |
48 |
O |
CO |
24 |
| D5.1 |
Acceptance and QC checking of all DNA samples at CNG & GSF |
5 |
Partner 3 |
12 |
O |
CO |
24 |
| D5.3 |
Phase II genotyping complete |
5 |
Partner 3 |
24 |
O |
CO |
20 |
|
| D5.4 |
Phase III genotyping complete |
5 |
Partner 3 |
24 |
O |
CO |
30 |
| D5.5 |
Proteomic examination of plasma asthmatics and controls |
5 |
Partner 2 |
4 |
O |
CO |
30 |
| D5.6 |
Proteomic examination of plasma farmers and controls |
5 |
Partner 2 |
4 |
O |
CO |
30 |
| D5.9 |
Database for phenotype and genotypes |
5 |
Partner 21 |
3 |
O |
CO |
13 |
| D5.11 |
Joint Phase II data analysed |
5 |
Partner 21 |
6 |
R |
PU |
22 |
| D6.2 |
Microbial components of dust samples from validation study |
6 |
Partner 8 |
6 |
O |
PU |
24 |
| D6.3 |
Components of milk samples from validation study |
6 |
Partner 8 |
6 |
O |
PU |
24 |
| D6.4 |
Revised protocols for full survey |
6 |
Partner 2 |
6 |
O |
PU |
30 |
| D6.9 |
Analyses of the effects of smoking, genes and environment in subjects from existing surveys |
6 |
Partner 20 |
18 |
R |
PU |
24 |
| D6.10 |
Analyses of the effects of genes and environment in industrial asthma |
6 |
Partner 11 |
12 |
R |
PU |
30 |
| D6.11 |
Extractions from pooled dust samples from rural areas in alpine regions and South-West Poland |
6 |
Partner 6 |
12 |
O |
CO |
30 |
| D7.1 |
Establishment of baseline genomic epithelial model |
7 |
Partner 1 |
12 |
O |
PU |
18 |
| D7.2 |
Knockdown of target genes by RNAi in epithelial model |
7 |
Partner 1 |
24 |
O |
CO |
30 |
|
| D7.3 |
Establishment of Dendritic Cell Th1 Th2 modulation model |
7 |
Partner 13 |
12 |
O |
CO |
15 |
| D7.5 |
Knockout of gene PCDH1 (protocadherin) in mouse |
7 |
Partner 20 |
12 |
O |
CO |
24 |
| D7.6 |
Test efects of PCDH1 knockout on cigarette smoke exposure |
7 |
Partner 20 |
24 |
O |
CO |
27 |
| D7.7 |
Test effects of environmental factors from WP6.4 on murine model of asthma |
7 |
Partner 16 |
36 |
O |
CO |
27 |
|
| D8.5 |
Selection of target from the results of WP3 and WP5 |
8 |
Partner 27 |
6 |
O |
CO |
18 |
| D8.6 |
Development of potential biotherapeutics against target |
8 |
Partner 27 |
36 |
O |
CO |
24 |
| D9.3 |
Call for 3-month visiting fellowships |
9 |
Partner 20 |
3 |
O |
PU |
15 |
| D9.4 |
Appointment of visting fellowships |
9 |
Partner 20 |
3 |
O |
PU |
18 |
9
59
1200
1200
3
37
8
False
False